echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Connaeus Biopharma successfully completed a Phase I single dose escalation trial of CBP-174

    Connaeus Biopharma successfully completed a Phase I single dose escalation trial of CBP-174

    • Last Update: 2022-09-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Connec Biomedical (NASDAQ: CNTB) ("Connad" or the "Company") is a globally developed biopharmaceutical company with clinical-stage products that develops innovative therapies through its self-developed T cell function modulation platform to improve the quality


    In this randomized, double-blind, placebo-controlled, single oral dose-escalation (SAD) trial, CBP-174 was observed to be safe and well tolerated in eight dose-escalating groups (up to a maximum dose of 16 mg or placebo), with no serious adverse events, and the reported adverse events were predominantly mild and no dose-limiting toxicity was


    "This positive data from the first human clinical trial shows that CBP-174 is making good progress as a new treatment for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, which plague millions of people worldwide," said Dr.


    Connec Biomedical (NASDAQ: CNTB) ("Connad" or the "Company") is a globally developed biopharmaceutical company with clinical-stage products that develops innovative therapies through its self-developed T cell function modulation platform to improve the quality


    In this randomized, double-blind, placebo-controlled, single oral dose-escalation (SAD) trial, CBP-174 was observed to be safe and well tolerated in eight dose-escalating groups (up to a maximum dose of 16 mg or placebo), with no serious adverse events, and the reported adverse events were predominantly mild and no dose-limiting toxicity was


    "This positive data from the first human clinical trial shows that CBP-174 is making good progress as a new treatment for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, which plague millions of people worldwide," said Dr.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.